The knowledge of BRAF and other MAPK pathway mutations has led to the use of BRAF and MEK inhibitors in prospective clinical trials of histiocytosis, including a small proportion of participants who have CNS LCH. This evidence concerns the gene BRAF and Histiocytosis.